FOSUN PHARMA Buys Back 2.00 Million H-Shares for HK$33.32 Million, Expanding Treasury Stock to 27.85 Million

Bulletin Express11-02

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (FOSUN PHARMA) disclosed that it repurchased 2.00 million H-shares on the Hong Kong Stock Exchange on 2 November 2026.

Key transaction details • Repurchase volume: 2.00 million H-shares, equal to 0.38 % of the company’s outstanding H-shares prior to the transaction. • Price range: HK$16.32–HK$16.85 per share; volume-weighted average price: HK$16.66. • Total consideration: HK$33.32 million. • Treatment: All repurchased shares are held as treasury shares.

Capital structure impact • Outstanding H-shares (ex-treasury) fell from 526.09 million to 524.09 million. • Treasury shares increased from 25.85 million to 27.85 million. • Total issued shares remained unchanged at 551.94 million.

Repurchase mandate utilisation • Authorised shares under mandate (approved 16 June 2026): 54.10 million. • Cumulative shares bought back under the mandate, including the latest tranche: 16.88 million, representing 3.12 % of the company’s issued H-shares on the mandate date. • Post-repurchase moratorium: No new share issues or treasury share disposals until 2 December 2026, in line with Hong Kong listing rules.

The company confirmed that all transactions complied with Main Board requirements and that no material changes have been made to the repurchase mandate’s explanatory statement.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1168391763?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-11-02 17:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1168391763","market":"us","top_or_hot":-1,"title":"FOSUN PHARMA Buys Back 2.00 Million H-Shares for HK$33.32 Million, Expanding Treasury Stock to 27.85 Million","media":"Bulletin Express","content":"<p>Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (FOSUN PHARMA) disclosed that it repurchased 2.00 million H-shares on the Hong Kong Stock Exchange on 2 November 2026.</p>\n<p>Key transaction details  \n• Repurchase volume: 2.00 million H-shares, equal to 0.38 % of the company’s outstanding H-shares prior to the transaction.  \n• Price range: HK$16.32–HK$16.85 per share; volume-weighted average price: HK$16.66.  \n• Total consideration: HK$33.32 million.  \n• Treatment: All repurchased shares are held as treasury shares.</p>\n<p>Capital structure impact  \n• Outstanding H-shares (ex-treasury) fell from 526.09 million to 524.09 million.  \n• Treasury shares increased from 25.85 million to 27.85 million.  \n• Total issued shares remained unchanged at 551.94 million.</p>\n<p>Repurchase mandate utilisation  \n• Authorised shares under mandate (approved 16 June 2026): 54.10 million.  \n• Cumulative shares bought back under the mandate, including the latest tranche: 16.88 million, representing 3.12 % of the company’s issued H-shares on the mandate date.  \n• Post-repurchase moratorium: No new share issues or treasury share disposals until 2 December 2026, in line with Hong Kong listing rules.</p>\n<p>The company confirmed that all transactions complied with Main Board requirements and that no material changes have been made to the repurchase mandate’s explanatory statement.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FOSUN PHARMA Buys Back 2.00 Million H-Shares for HK$33.32 Million, Expanding Treasury Stock to 27.85 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFOSUN PHARMA Buys Back 2.00 Million H-Shares for HK$33.32 Million, Expanding Treasury Stock to 27.85 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-11-02 17:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (FOSUN PHARMA) disclosed that it repurchased 2.00 million H-shares on the Hong Kong Stock Exchange on 2 November 2026.</p>\n<p>Key transaction details  \n• Repurchase volume: 2.00 million H-shares, equal to 0.38 % of the company’s outstanding H-shares prior to the transaction.  \n• Price range: HK$16.32–HK$16.85 per share; volume-weighted average price: HK$16.66.  \n• Total consideration: HK$33.32 million.  \n• Treatment: All repurchased shares are held as treasury shares.</p>\n<p>Capital structure impact  \n• Outstanding H-shares (ex-treasury) fell from 526.09 million to 524.09 million.  \n• Treasury shares increased from 25.85 million to 27.85 million.  \n• Total issued shares remained unchanged at 551.94 million.</p>\n<p>Repurchase mandate utilisation  \n• Authorised shares under mandate (approved 16 June 2026): 54.10 million.  \n• Cumulative shares bought back under the mandate, including the latest tranche: 16.88 million, representing 3.12 % of the company’s issued H-shares on the mandate date.  \n• Post-repurchase moratorium: No new share issues or treasury share disposals until 2 December 2026, in line with Hong Kong listing rules.</p>\n<p>The company confirmed that all transactions complied with Main Board requirements and that no material changes have been made to the repurchase mandate’s explanatory statement.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02196","symbol_name":"复星医药","start_time":0,"source_url":"","article_id":"1168391763","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1168391763","pubTimestamp":1793611773,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (FOSUN PHARMA) disclosed that it repurchased 2.00 million H-shares on the Hong Kong Stock Exchange on 2 November 2026. Key transaction details   •...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02196":"复星医药"},"translate_title":"复星医药以3332万港元回购200万股H股，库存股扩大至2785万股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02196":1},"content_text":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (FOSUN PHARMA) disclosed that it repurchased 2.00 million H-shares on the Hong Kong Stock Exchange on 2 November 2026.\nKey transaction details  \n• Repurchase volume: 2.00 million H-shares, equal to 0.38 % of the company’s outstanding H-shares prior to the transaction.  \n• Price range: HK$16.32–HK$16.85 per share; volume-weighted average price: HK$16.66.  \n• Total consideration: HK$33.32 million.  \n• Treatment: All repurchased shares are held as treasury shares.\nCapital structure impact  \n• Outstanding H-shares (ex-treasury) fell from 526.09 million to 524.09 million.  \n• Treasury shares increased from 25.85 million to 27.85 million.  \n• Total issued shares remained unchanged at 551.94 million.\nRepurchase mandate utilisation  \n• Authorised shares under mandate (approved 16 June 2026): 54.10 million.  \n• Cumulative shares bought back under the mandate, including the latest tranche: 16.88 million, representing 3.12 % of the company’s issued H-shares on the mandate date.  \n• Post-repurchase moratorium: No new share issues or treasury share disposals until 2 December 2026, in line with Hong Kong listing rules.\nThe company confirmed that all transactions complied with Main Board requirements and that no material changes have been made to the repurchase mandate’s explanatory statement.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1168391763","isCrawlerRequest":true}